This article is more than 5 years old. Information may no longer be current.
Lymphoma specialist named associate director for clinical services at Rutgers Cancer Institute
Click Here to Manage Email Alerts
Andrew M. Evens, DO, MSc, FACP, has been named associate director for clinical services at Rutgers Cancer Institute.
In this role, he will oversee and facilitate integration of all multidisciplinary clinical programs across the institute, including those focused on palliative care, navigational support and survivorship.
Evens also will serve as director of the lymphoma program in the division of blood disorders, medical director of the oncology service line at RWJBarnabas Health, and professor of medicine at Rutgers Robert Wood Johnson Medical School.
“Dr. Evens’ leadership skills and clinical expertise complement the mission of Rutgers Cancer Institute — the state’s only NCI-designated comprehensive cancer center — in delivering the highest quality of cancer care,” Steven K. Libutti, MD, FACS, director of Rutgers Cancer Institute, senior vice president of oncology services for RWJBarnabas Health and vice chancellor for cancer programs for Rutgers Biomedical and Health Sciences, said in a press release. “His role in enhancing integrated cancer care in concert with RWJBarnabas Health will promote the growth of clinical research and clinical services that will enable us to further address the oncology needs of the state of New Jersey and beyond.”
Evens most recently served as director of the cancer center at Tufts Medical Center. He also served as chief of the division of hematology/oncology.
He is recognized for his expertise in the treatment, biology and prognosis of Hodgkin lymphoma and non-Hodgkin lymphoma.
“I look forward to helping enhance the clinical mission of both Rutgers Cancer Institute and RWJBarnabas Health,” Evens said in the release. “By further emphasizing the strengths of our collective advanced clinical offerings and exploring innovative opportunities for improved and additional cancer care services, we will have a valuable impact on oncology outcomes for patients across the region.”